Ignite Creation Date:
2024-05-06 @ 3:28 PM
Last Modification Date:
2024-10-26 @ 1:50 PM
Study NCT ID:
NCT04647526
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-19
First Post:
2020-11-23
Brief Title:
Study Evaluating mCRPC Treatment Using PSMA Lu-177-PNT2002 Therapy After Second-line Hormonal Treatment
Sponsor:
POINT Biopharma a wholly owned subsidiary of Eli Lilly and Company
Organization:
POINT Biopharma a wholly owned subsidiary of Eli Lilly and Company
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-02-25
Start Date Type:
ACTUAL
Primary Completion Date:
2023-11-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2028-03
Completion Date Type:
ESTIMATED
First Submit Date:
2020-11-23
First Submit QC Date:
November 23 2020
Study First Post Date:
2020-12-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-18
Last Update Post Date:
2024-04-19
Last Update Post Date Type:
ACTUAL